Abstract:Glaucoma is one of the main causes of irreversible blindness, producing 12.3% of blindness worldwide. There are about 4.5 million people with glaucoma in the world. However, the real number should be much higher if we consider all people with undiagnosed glaucoma. Glaucoma is an age‐related multifactorial disease determined by both genetic and environmental factors. The cause remains unknown. So, efforts are focused on preventing blindness through early diagnosis and hypotensive treatment, which is not always effective. Currently, neuroprotective treatment is also considered. Among the most studied processes in relation to optic nerve degeneration in glaucoma are inflammation and apoptosis. Several studies show that genes associated with inflammation are upregulated in the trabecular meshwork, which could be related to the onset or progression of glaucoma. However, the most visible manifestations of inflammation in glaucoma occur on the ocular surface. This produces, for example, an infiltration of inflammatory cells and a reduction in corneal sensitivity. Like inflammatory processes, apoptosis has been associated with glaucomatous disease. In fact, vision loss is caused by the death of retinal ganglion cells (RGCs), whose axons form the fibres of the optic nerve. The survival of RGCs is key to the prevention of glaucomatous blindness. The ocular microbiota has recently been studied, analysing the possible association between the inflammatory molecules produced by the ocular microbiome and the etiopathogenic mechanisms of this optic neuropathy. The aim of these studies is the development of probiotics as a therapy for glaucoma. Probiotic strains allow a rapid and stable recovery of the normal ocular microbiota, providing faster anti‐inflammatory and antihistamine effects. In addition, they are antagonists of the pathogens without the risk of the appearance of resistance, which avoids the use of antibiotics. In this way, probiotics represent an alternative to the abusive use of antibiotics, thus avoiding the problem of resistance development. In this sense, polyphenols are very interesting since they are capable of exerting neuroprotective and immunomodulatory effects and also can remodel the microbiota.

The gut microbiome and primary open angle glaucoma: Evidence for a 'gut-glaucoma' axis?

Glaucoma and the Human Microbiome

The role of the microbiota in glaucoma

Dysbiosis of Gut Microbiome Contributes to Glaucoma Pathogenesis

Bacterial Insights: Unraveling the Ocular Microbiome in Glaucoma Pathogenesis

Exploring the Ocular Surface Microbiome and Tear Proteome in Glaucoma

A higher abundance of butyrate‐producing taxa in the gut is associated with lower glaucoma prevalence

Gut microbiota and derived metabolomic profiling in glaucoma with progressive neurodegeneration

Glaucoma Patients Have a Lower Abundance of Butyrate-Producing Taxa in the Gut

Microbiome Dysbiosis: A Pathological Mechanism at the Intersection of Obesity and Glaucoma

Causal relationships between Gut microbiota and primary open-angle Glaucoma: A Mendelian randomization and mediation analysis of Glaucoma endophenotypes

Immunonutrition in glaucoma patients: A new microbiota‐based treatment

Impact of the Gut Microbiota and Associated Metabolites on Primary Open Angle Glaucoma

The correlation between primary open-angle glaucoma (POAG) and gut microbiota: a pilot study towards predictive, preventive, and personalized medicine

Neuroinflammation and microglia in glaucoma: time for a paradigm shift

Effect of the Gut Microbiome in Glaucoma Risk from the Causal Perspective

The gut-eye axis: the retinal/ocular degenerative diseases and the emergent therapeutic strategies

Gut microbiome in ocular health and disease

How gut microbiota may impact ocular surface homeostasis and related disorders

Modifiable factors in the management of glaucoma: a systematic review of current evidence

The Association between Vascular Abnormalities and Glaucoma—What Comes First?